Page 136 - Functional impairment and cues for rehabilitation of head and neck cancer patients -

Chapter 5
134
Appendix 3 Continued
Symptoms
n = 42 11 (0-79) 1 (0-67) 19 (68)
9 (32)
14
n = 39 15 (0-36) 6 (0-41) 15 (68)
7 (32)
17
n = 28 13 (0-27) 2 (0-31) 21 (91)
2 (9)
5
n = 17 5 (0-21) 3 (0-28) 12 (86) 2 (14)
3
n = 17 14 (5-52) 21 (0-77) 5 (39)
8 (62)
4
n = 11 15 (0-23) 25 (0-32) 3 (38)
5 (63)
3
n = 49
7 (0-48) 10 (0-69) 21 (58) 15 (42) 12
n = 43 20 (0-48) 18 (0-57) 15 (47) 17 (53) 11
n = 32 14 (0-41) 10 (0-43) 14 (64)
8 (36)
10
Total score SWAL-QOL ≥ 14
No
Yes Unknown
Secondary outcomes
Feeding tube
No
Yes NGT Yes PRG Unknown No
Yes Unknown
41 (98) 1 (2)
0 (0)
0
39 (100) 0 (0)
0 (0)
0
28 (100) 0 (0)
0 (0)
0
17 (100) 0 (0)
0 (0)
0
15 (88) 0 (0)
2 (12) 0
11 (100) 0 (0)
0 (0)
0
48 (98) 0 (0)
1 (2)
0
39 (91) 0 (0)
4 (9)
0
32 (100) 0 (0)
0 (0)
0
Pneumonia
40 (95) 2 (5)
0
34 (97) 1 (3)
4
27 (96) 1 (4)
0
16 (94) 1 (6)
0
16 (94) 1 (6)
0
10 (91) 1 (9)
0
42 (98) 1 (2)
6
40 (98) 1 (2)
2
30 (97) 1 (3)
1
RT RT + cetuximab RT + cisplatin
t0 t1 t2 t0 t1 t2 t0 t1 t2
NB: Not all percentages sum up exactly to 100% due to rounding.
Abbreviations: FOIS = functional oral intake scale, t0 = pretreatment, t1 = six months after treatment, t2 = twelve months after treatment.